Editors' Note: This article covers a micro-cap stock. Please be aware of the risks associated with these stocks.
Shares of Titan Pharmaceuticals (NASDAQ:TTNP) have been stuck in a narrow trading range between $0.45 and $0.65 for the past 4+ months following the surprise decision from the U.S. FDA to issue a complete response letter (CRL) for Probuphine back in late April 2013. We call this decision by the FDA a "surprise", because only five weeks prior to the decision, in March 2013, the FDA's Psychopharmacologic Drugs Advisory Committee (PDAC) voted to recommend approval of the product. Titan plans to request a meeting with the FDA to discuss the issues raised in the CRL in the next few weeks....
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|